Related Experiment Video
Updated: May 3, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
13.7K
Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Ioannis Gounaris1, Helen M Hatcher, Dochka Davidson
1Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Future Oncology (London, England)
|January 24, 2014
Summary
Trabectedin shows efficacy in heavily pretreated soft tissue sarcoma patients, with a 60% clinical benefit rate. Adjusting the trabectedin schedule and dexamethasone effectively managed fatigue without reducing effectiveness.
Area of Science:
- Oncology
- Pharmacology
Background:
- Retrospective analysis of trabectedin treatment in soft tissue sarcoma patients.
- Data collected from April 2009 to August 2011.
Purpose of the Study:
- To assess the efficacy and safety of trabectedin in recurrent soft tissue sarcoma.
- To evaluate trabectedin at a dose of 1.5 mg/m² every 3 weeks.
Main Methods:
- Analysis of 25 patients with recurrent soft tissue sarcoma (leiomyosarcoma and liposarcoma).
- Assessment of treatment response based on dimensional and tumor density changes.
- Monitoring of adverse events.
Main Results:
- 32% partial response rate and 28% stable disease for ≥ 3 months (60% clinical benefit rate).
- Median progression-free survival of 6.4 months and overall survival of 19.3 months.
- Common adverse events included fatigue, nausea, anemia, and transient transaminase increases.
Conclusions:
- Trabectedin is effective and well-tolerated in heavily pretreated soft tissue sarcoma patients.
- Dexamethasone tapering and an every 4 weeks trabectedin schedule managed fatigue effectively.
- The modified treatment approach maintained effectiveness while improving tolerability.
